



24 <sup>7</sup>Department of Respiratory Medicine, Isahaya General Hospital, Nagasaki, Japan

25 <sup>8</sup>Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate

26 School of Biomedical Sciences, Nagasaki, Japan

27 <sup>9</sup>Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

28 <sup>10</sup>Department of Clinical Oncology, Nagasaki University Graduate School of

29 Biomedical Sciences, Nagasaki, Japan

30 <sup>11</sup>Department of Radiology, University of Occupational and Environmental Health,

31 Japan, Fukuoka, Japan

32

33 \*Corresponding author

34 E-mail: [kazukomd@nagasaki-u.ac.jp](mailto:kazukomd@nagasaki-u.ac.jp) (KY)

35

36

## 37 **Abstract**

38 Rheumatoid arthritis frequently complicates airway diseases and is associated  
39 with high rates of pneumonia and mortality. The relationship between microorganisms  
40 colonizing the lower respiratory tract and the subsequent incidence of pneumonia in  
41 patients with rheumatoid arthritis is unclear. In this study, we aimed to identify  
42 microorganisms colonizing the lower respiratory tract in patients with rheumatoid  
43 arthritis related to the risk of developing subsequent pneumonia in these patients.

44 A retrospective cohort study was designed to include a total of 121 patients with  
45 rheumatoid arthritis (median age, 67 years; women, 78.5%) who underwent  
46 bronchoscopy at three hospitals from January 2008 to December 2017. The following  
47 information was extracted from their electronic medical records: patient characteristics,  
48 microorganisms detected by bronchoscopy, and subsequent incidences of pneumonia.  
49 The patients were divided into groups based on the microorganisms isolated from the  
50 lower respiratory tract and compared with control subjects. The cumulative incidence of  
51 pneumonia was assessed using the Kaplan–Meier method and log-rank test. Risk factors  
52 for pneumonia were analyzed using the Cox proportional-hazards analysis.

53 The most frequently isolated microbes from the lower respiratory tract in  
54 descending order were *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and  
55 *Haemophilus influenzae*. The annual incidence rates of pneumonia per 1000 patients  
56 were 100, 62, 132, and 38, in the *P. aeruginosa*, *S. aureus*, *H. influenzae*, and control  
57 group, respectively. Patients colonized with *P. aeruginosa* had a higher frequency of  
58 macrolide use and a higher degree of bronchiectasis than patients in the control group.  
59 The rate of the subsequent incidence of pneumonia was higher in the *P. aeruginosa*

60 group ( $P = 0.038$ ), and *P. aeruginosa* was an independent risk factor for  
61 pneumonia (hazard ratio, 3.504; 95% confidence interval, 1.153–10.330).

62 The colonization of the lower respiratory tract by *P. aeruginosa* in patients with  
63 rheumatoid arthritis was associated with the subsequent incidence of pneumonia.

## 64 **Introduction**

65 The high incidence of pneumonia and associated mortality in patients with  
66 rheumatoid arthritis (RA) is a critical concern [1]. Airway diseases (ADs) such as  
67 bronchiectasis are common complications of RA, with a rate of 10–30% [2, 3]; patients  
68 with RA and ADs have a significantly poor prognosis [4]. *Pseudomonas aeruginosa*  
69 increases the risk of mortality and exacerbation in patients with bronchiectasis [4, 5];  
70 however, the relationship between airway colonization and the incidence of pneumonia  
71 in patients with RA has not yet been clarified. Thus, we aimed to identify whether  
72 colonization of the lower respiratory tract (LRT) by microorganisms, particularly  
73 *P. aeruginosa*, correlated with the occurrence of pneumonia in patients with RA.

## 74 **Materials and methods**

### 75 **Patients and study design**

76 This retrospective cohort study was conducted at the Nagasaki University  
77 Hospital, University of Occupational and Environmental Health, Japan, and Isahaya  
78 General Hospital, from January 2008 to December 2017. This multicenter study was  
79 conducted in compliance with the Declaration of Helsinki and was approved by the  
80 Ethics Committees of the participating institutions (Nagasaki University Hospital,  
81 Approval Number: 19061714; University of Occupational and Environmental Health,

82 Japan, Approval Number: 19-044; Isahaya General Hospital, Approval  
83 Number: 2020-9). The requirement for patient consent was waived due to the  
84 retrospective nature of the study, which ensured anonymity.

85 The inclusion criteria were as follows: age  $\geq 20$  years, an RA diagnosis by  
86 rheumatologists certified by the Japan College of Rheumatology [6], and bronchoscopy  
87 performed by a pulmonary physician. We excluded patients if they had active infections  
88 requiring antimicrobial agents at the time of bronchoscopy; malignancy diagnosed  
89 within five years of the study; tracheotomy; cystic fibrosis (CF); or at least one of the  
90 following conditions: human immunodeficiency virus infection, a CD4 cell count  
91  $< 350/\mu\text{L}$ , solid organ transplantation, or neutropenia  $< 500$  cells/ $\mu\text{L}$ . Patient  
92 characteristics and RA status were extracted from the hospital's electronic medical  
93 records.

## 94 **Evaluation of bronchiectasis**

95 Chest computed tomography (CT) was performed before bronchoscopy.  
96 Bronchiectasis was assessed by blinded reads, based on the modified Reiff score [4], by  
97 two board-certified radiologists from the Japanese Radiological Society with an average  
98 experience of 25 years. The Reiff score indicates the degree of bronchial  
99 dilatation (tubular, 1; varicose, 2; and cystic, 3) and number of lobes involved. The  
100 lingular segment was evaluated as an independent lobe. Scores ranged from 1 to 18, and  
101 patients without bronchodilation were assigned a score of 0.

## 102 **Identification of the lower respiratory tract-colonizing** 103 **microbes**

104 To detect the colonizing microorganisms in the LRT, bronchial lavage or  
105 intratracheal sputum collected by bronchoscopy was directly cultured using blood with  
106 chocolate agar (37 °C, 5% CO<sub>2</sub>), anero Columbia agar (anaerobic chamber), and bromo  
107 thymol blue with chromagar (37 °C) for detecting gram-positive, gram-negative, and  
108 anaerobic bacteria and fungi.

## 109 **Endpoint**

110 The data were censored on March 31, 2019. Pneumonia incidence and  
111 pneumonia-free survival, calculated from the date of bronchoscopy to the date of  
112 pneumonia diagnosis, were recorded. Patients who did not develop pneumonia or who  
113 were lost to follow-up were censored at the date of last contact. Pneumonia was  
114 confirmed by the presence of new lung infiltrates and at least one of the following acute  
115 respiratory symptoms: cough, sputum production, dyspnea, a body temperature of  
116  $\geq 38.0$  °C, abnormal auscultatory findings, and leukocyte counts of  $>10000$  cells/ $\mu$ L or  
117  $<4000$  cells/ $\mu$ L.

## 118 **Statistical analysis**

119 The Mann–Whitney U test was used for analyzing continuous variables, and  
120 Fisher’s exact test for categorical variables. The cumulative incidence of pneumonia  
121 was estimated using the Kaplan–Meier method and log-rank test. Baseline variables  
122 with a *P*-value  $<0.10$  (by univariate analysis) and previously reported risk factors for  
123 pneumonia in patients with RA were included in the multivariate analysis. The risk of  
124 pneumonia was evaluated using Cox proportional-hazards models (CPHM) to  
125 determine hazard ratios (HRs) with 95% confidence intervals (95% CIs). A *P*-value

126 <0.05 was considered statistically significant. Analyses were performed using  
127 JMP<sup>®</sup> 13 (SAS Institute Inc., Cary, NC, USA).

## 128 **Results**

### 129 **Eligible patients**

130           Among the 228 patients with RA who underwent bronchoscopy during the  
131 study period, 107 were excluded from the study, including 71 with active  
132 infections (pneumonia, 43; non-tuberculosis mycobacteria, 16; cryptococcosis, 7;  
133 aspergillosis, 3; *Pneumocystis*, 1; and other mycosis, 1); 33 with malignancies (lung, 28;  
134 renal, esophageal, ovarian, endometrial, and adult T-cell leukemia-lymphoma; 1 each);  
135 1 with a tracheotomy; and 1 with solid organ transplantation. No data were available for  
136 1 patient who was also excluded. Consequently, 121 patients were included in the  
137 study (Fig 1).

138 **Fig 1. Selection of eligible patients.** RA, rheumatoid arthritis

### 139 **Lower respiratory tract colonization by microbes**

140           The detected microbes in the LRT samples are listed in Table 1. The LRT  
141 samples tested positive in 100 patients (82.6%), including 41 (33.9%) with normal oral  
142 flora. Among the frequently isolated pathogens, *P. aeruginosa* (13.2%), *Staphylococcus*  
143 *aureus* (12.4%), and *Haemophilus influenzae* (5.0%) were the most prominent. The  
144 other pathogens were *Streptococcus pneumoniae* (1.7%), other streptococci (3.3%),  
145 other gram-negative bacilli (5.0%), anaerobic bacteria (1.7%), nontuberculous  
146 mycobacteria (4.1%), *Candida* species (3.3%), and other fungi (2.5%).

147 **Table 1. Microorganisms detected by bronchoscopy**

Organism	Number (%)
<i>Pseudomonas aeruginosa</i>	16 (13.2)
<i>Staphylococcus aureus</i>	15 (12.4)
<i>Haemophilus influenzae</i>	6 (5.0)
<i>Streptococcus pneumoniae</i>	2 (1.7)
Other streptococci	4 (3.3)
Anaerobic bacteria	2 (1.7)
<i>Candida</i> species	4 (3.3)
Other fungi	3 (2.5)
Other microbes <sup>a</sup>	11 (9.1)
Oral flora	41 (33.9)
Negative	21 (17.4)

148 <sup>a</sup>*Stenotrophomonas maltophilia*, *Burkholderia cepacia*, *Klebsiella oxytoca*,

149 *P. fluorescens*, *Serratia marcescens*, *Mycobacterium intracellulare*, and *M. goodnae*.

150 **Patient groups based on the lower respiratory tract-colonizing**  
151 **microbes**

152 Patients with RA were divided into groups depending on the microorganisms  
153 isolated from the LRT—*P. aeruginosa* (*Pa* group), *S. aureus* (*Sa* group), and  
154 *H. influenzae* (*Hi* group). The others, including those whose samples tested  
155 negative (n = 21) or positive for normal oral flora and other pathogens (n = 22), were  
156 considered as the control group and were compared with the abovementioned bacteria  
157 groups (Table 2).

158 **Table 2. Characteristics of patients with RA, including those whose lower**  
 159 **respiratory tract was colonized by each of the three major bacterial species**

	Total (n = 121)	<i>Pseudomonas</i> <i>aeruginosa</i> (n = 16)	<i>Staphylococcus</i> <i>aureus</i> (n = 15)	<i>Haemophilus</i> <i>influenzae</i> (n = 6)	Control (n = 84)
Age (years)	67 (61–76)	66 (61–76)	63 (58–76)	69 (64–75)	68 (61–76)
Female patients, %	78.5	87.5	93.3	66.7	75.0
Performance status	1 (0–1)	* 0 (0–1)	1 (0–1)	1 (0–1)	1 (0–1)
Smoking (pack-year)	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–43)	0 (0–2)
Duration of RA (years)	5.2 (0.6–15.6)	3.1 (0.5–8.7)	3.4 (0.1–11.1)	5.8 (1.9–19.7)	5.4 (0.6–16.1)
DAS28-ESR	4.8 (3.7–6.0)	5.4 (4.1–6.2)	4.6 (3.2–5.7)	4.4 (3.5–4.8)	5.1 (3.7–6.4)
MTX use, %	51.2	62.5	53.3	33.3	50.0
GC use, %	36.4	37.5	* 6.7	33.3	41.7
GC dosage <sup>‡</sup> , mg/day	0 (0–3)	0 (0–3)	* 0 (0–0)	0 (0–3)	0 (0–4)
Duration of GC use (months)	0 (0–22)	0 (0–41)	* 0 (0–0)	0 (0–44)	0 (0–27)
Biologics use, %	22.3	25.0	26.7	16.7	21.4
Macrolide use, %	14.9	* 43.8	26.7	0	8.3
DM, %	8.4	12.5	6.7	16.7	7.1
ILD, %	33.9	18.8	* 6.7	33.3	41.7
COPD, %	6.6	12.5	0	16.7	6.0
Modified Reiff score	2 (0–3)	* 6.5 (4–10.8)	* 6 (2–12)	1.5 (0.8–7.8)	4 (0.3–6)
Observation period	41 (18–68)	41 (20–86)	45 (6–68)	55 (22–92)	41 (20–65)

(months)

---

160 Data are presented as frequency (%) or median (interquartile range)  
161 RA, rheumatoid arthritis; DM, diabetes mellitus; ILD, interstitial lung disease;  
162 COPD, chronic obstructive pulmonary disease; MTX, methotrexate;  
163 GC, glucocorticoid; DAS, disease activity score; ESR, erythrocyte sedimentation rate.  
164 \*P <0.05 compared to the control group  
165 ‡Prednisolone dosage

166 **Patient backgrounds per group (based on the lower**  
167 **respiratory tract-colonizing microbes)**

168 The age, sex, smoking history, RA duration, and observation period were not  
169 different among the groups. The incidence of diabetes mellitus (DM), chronic  
170 obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) was  
171 relatively low in the *Sa* group. None of the patients in the *Sa* group used  
172 glucocorticoids (GCs). Long-term macrolides ( $\geq 1$  month) were more commonly  
173 implemented in the *Pa* group. The *Pa* and *Sa* groups showed a significantly higher  
174 degree of bronchiectasis, detected by the modified Reiff score.

175 **Incidence and hazard ratios of pneumonia**

176 The annual incidence rates of pneumonia per 1000 patients were 100, 62, 132,  
177 and 38, in the *Pa*, *Sa*, *Hi*, and control groups, respectively. Kaplan–Meier curves are  
178 shown in Fig 2. Log-rank tests revealed that the *Pa* group had a significantly higher  
179 incidence of pneumonia ( $P = 0.038$ ). The *Hi* group was not analyzed using CPHM since  
180 no proportional hazard was established. *S. aureus* colonization was not a statistically  
181 significant risk factor for subsequent pneumonia. To compare the *Pa* group with the

182 control group, the HRs were adjusted for age, sex, performance status, DM, ILD, COPD,  
183 GCs, and the modified Reiff score using CPHM. *P. aeruginosa* colonization was an  
184 independent risk factor for pneumonia in patients with RA (HR, 3.504; 95% CI,  
185 1.153–10.330; Table 3).

186 **Fig 2. Kaplan–Meier plots and number-at-risk tables for the probability of**  
187 **pneumonia-free survival.** Control group: patients with microbes other than  
188 *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Haemophilus influenzae*.

189 **Table 3. Hazard ratios for pneumonia.**

	Univariate analysis		Multivariate analysis	
	HR (95% CI)	<i>P</i> -value	HR (95% CI)	<i>P</i> -value
Age	1.039 (0.991–1.094)	0.119	0.999 (0.939–1.067)	0.971
Female sex	0.547 (0.203–1.726)	0.281	0.549 (0.139–2.385)	0.409
Smoking	1.007 (0.983–1.023)	0.526		
Performance status	1.468 (0.780–2.561)	0.222	1.354 (0.612–2.798)	0.431
DM	3.860 (0.873–12.228)	0.071	1.714 (0.307–7.951)	0.515
ILD	1.794 (0.721–4.527)	0.201	2.554 (0.831–8.169)	0.102
COPD	3.547 (0.815–10.929)	0.084	1.624 (0.304–7.647)	0.546
Duration of RA	1.022 (0.982–1.057)	0.264		
MTX	0.770 (0.308–1.951)	0.574		
GC use	1.564 (0.617–3.912)	0.338	1.319 (0.405–4.061)	0.636
Biologics	0.824 (0.234–2.284)	0.728		
Macrolide	0.799 (0.183–2.457)	0.719		

DAS28-ESR	0.946 (0.664–1.356)	0.760		
Modified Reiff score	1.106 (0.983–1.247)	0.093	1.135 (0.982–1.311)	0.084
<i>Pa</i> colonization	2.636 (0.965–6.727)	0.058	3.504 (1.153–10.330)	0.028

---

190 HR, hazard ratio; CI, confidence interval; ILD, interstitial lung disease; COPD, chronic  
191 obstructive pulmonary disease; RA, rheumatoid arthritis; MTX, methotrexate;  
192 GC, glucocorticoid; DAS, disease activity score; ESR, erythrocyte sedimentation rate;  
193 *Pa*, *Pseudomonas aeruginosa*

## 194 Discussion

195 We retrospectively analyzed pneumonia in patients with RA based on the  
196 microbes that colonized the LRT. *P. aeruginosa*, *S. aureus*, and *H. influenzae* were the  
197 most frequent colonizers, and *P. aeruginosa* colonization was an independent risk factor  
198 for subsequent pneumonia in patients with RA. The annual incidence rate of pneumonia  
199 per 1000 patients in these three groups was higher than that in the control group, while  
200 the frequency of pneumonia in the control group in this study was similar to the  
201 frequency in patients with RA in a previous study [7]. To the best of our knowledge,  
202 this is the first study that focuses on microbial colonization of the LRT as a risk factor  
203 for pneumonia in patients with RA. The strength of this study was the evaluation of  
204 microbes by bronchoscopy, minimizing oral bacterial contamination and reflecting  
205 LRT-specific flora. Another strength was the novel approach to evaluate whether  
206 colonized *P. aeruginosa* was directly correlated with subsequent pneumonia in patients  
207 with RA.

208 *P. aeruginosa* has been reported as one of the major causative  
209 microorganisms of pneumonia in patients with RA [1]. The risks of pneumonia in the  
210 *Pa* group may have been underestimated in this study due to frequent macrolide use in  
211 older patients. Long-term macrolide treatment can reduce pulmonary exacerbation and  
212 improve bronchiectasis in non-CF [8, 9]; moreover, macrolides possibly prevent  
213 pneumonia in older adults [10]. A relatively higher prevalence of DM and high-degree  
214 bronchiectasis in the *Pa* group may also have affected pneumonia incidences.

215 Conventional culture methods in non-CF patients with bronchiectasis tend to  
216 under-recognize *H. influenzae*, compared to *P. aeruginosa* and *S. aureus* [11].  
217 Therefore, the high incidence of pneumonia in the *Hi* group reported herein might be  
218 due to the small sample size. Further, most cases of pneumonia in the *Hi* group occurred  
219 more than 5 years after colonization, and *P. aeruginosa* was detected in the sputum of  
220 two-thirds of the patients who developed pneumonia; thus, microbial substitution by  
221 *P. aeruginosa* was possibly related to the incidence of pneumonia in the *Hi* group.

222 Reportedly, *P. aeruginosa* and *H. influenzae* are the most frequent colonizers of  
223 the LRT in patients with non-CF bronchiectasis [12, 13]. They were also the major  
224 colonizers and were isolated in cases of bronchiectasis in patients with RA in our study.  
225 *S. aureus* colonization with bronchiectasis is associated with CF or allergic  
226 bronchopulmonary aspergillosis [13, 14], although neither was seen in our patients.

227 The present study has several limitations. First, this study was a retrospective  
228 study, and the sample size was small. The history of pneumococcal vaccination was  
229 unavailable in the medical records, which might have affected the incidence of  
230 pneumonia. Second, the detected microorganisms did not reflect the information of the  
231 entire LRT. Furthermore, the conventional culture method has a limit when detecting

232 bacteria, and anaerobic bacteria may have been underestimated [15]. Third, only one  
233 point was assessed, and it is unclear if microbial substitution occurred after  
234 bronchoscopy. To accurately understand the effect of airway microbes on pneumonia in  
235 patients with RA, prospective studies with larger samples are required in the future.

## 236 **Conclusions**

237 In patients with RA, *P. aeruginosa*, *S. aureus*, and *H. influenzae* were the three  
238 major microbes isolated from the LRT, and the incidence of pneumonia was higher in  
239 these patients compared to the control group. *P. aeruginosa* colonization was associated  
240 with subsequent pneumonia in patients with RA. Our findings may contribute to the  
241 management of patients with RA whose LRT is colonized by *P. aeruginosa* by limiting  
242 unnecessary GC use, encouraging pneumococcal vaccination, and selecting  
243 antimicrobials that affect *P. aeruginosa* in the empiric treatment of pneumonia.

244

245 **Acknowledgments**

246           None.

247

## 248 **References**

- 249 1. Wakabayashi A, Ishiguro T, Takaku Y, Miyahara Y, Kagiya N,  
250 Takayanagi N. Clinical characteristics and prognostic factors of  
251 pneumonia in patients with and without rheumatoid arthritis. *PLoS*  
252 *One* 2018;13 8: e0201799.
- 253 2. Mohd Noor N, Mohd Shahrir MS, Shahid MS, Abdul Manap R, Shahizon Azura  
254 AM, Azhar Shah S. Clinical and high resolution computed tomography  
255 characteristics of patients with rheumatoid arthritis lung disease.  
256 *Int J Rheum Dis* 2009;12 2: 136-44.
- 257 3. Mori S, Koga Y, Sugimoto M. Different risk factors between  
258 interstitial lung disease and airway disease in rheumatoid arthritis.  
259 *Respir Med* 2012;106 11: 1591-9.
- 260 4. De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison  
261 J et al. Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent  
262 Risk Factor for Mortality in Patients With Bronchiectasis. *Chest*  
263 2017;151 6: 1247-54.
- 264 5. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A  
265 Comprehensive Analysis of the Impact of *Pseudomonas*  
266 *aeruginosa* Colonisation on Prognosis in Adult Bronchiectasis. *Annals*  
267 *of the American Thoracic Society* 2015;12 11: 1602-11.
- 268 6. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO,  
269 3rd et al. 2010 rheumatoid arthritis classification criteria: an  
270 American College of Rheumatology/European League Against Rheumatism  
271 collaborative initiative. *Ann Rheum Dis* 2010;69 9: 1580-8.
- 272 7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency  
273 of infection in patients with rheumatoid arthritis compared with  
274 controls: a population-based study. *Arthritis Rheum* 2002;46 9:  
275 2287-93.
- 276 8. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K et al.  
277 Long-term efficacy and safety of clarithromycin treatment in  
278 patients with diffuse panbronchiolitis. *Respiratory Medicine*  
279 2003;97 7: 844-50.
- 280 9. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of  
281 long-term macrolide treatment on respiratory microbiota composition  
282 in non-cystic fibrosis bronchiectasis: an analysis from the  
283 randomised, double-blind, placebo-controlled BLESS trial. *The*  
284 *Lancet Respiratory Medicine* 2014;2 12: 988-96.
- 285 10. Yoshikawa H, Komiya K, Umeki K, Kadota J-i. Long-Term Macrolide  
286 Antibiotic Therapy May Prevent the Development of Pneumonia in the  
287 Elderly. *Journal of Palliative Medicine* 2014;17 7: 749-50.

- 288 11. Cox MJ, Turek EM, Hennessy C, Mirza GK, James PL, Coleman M et al.  
289 Longitudinal assessment of sputum microbiome by sequencing of the  
290 16S rRNA gene in non-cystic fibrosis bronchiectasis patients. *PLoS*  
291 *One* 2017;12 2: e0170622.
- 292 12. Dimakou K, Triantafillidou C, Toumbis M, Tsikritsaki K, Malagari K,  
293 Bakakos P. Non CF-bronchiectasis: Aetiologic approach, clinical,  
294 radiological, microbiological and functional profile in 277 patients.  
295 *Respiratory Medicine* 2016;116: 1-7.
- 296 13. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden  
297 RA et al. An investigation into causative factors in patients with  
298 bronchiectasis. *Am J Respir Crit Care Med* 2000;162 4 Pt 1: 1277-84.
- 299 14. Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R.  
300 Determinants of chronic infection with *Staphylococcus aureus* in  
301 patients with bronchiectasis. *Eur Respir J* 1999;14 6: 1340-4.
- 302 15. Yamasaki K, Mukae H, Kawanami T, Fukuda K, Noguchi S, Akata K et al.  
303 Possible role of anaerobes in the pathogenesis of nontuberculous  
304 mycobacterial infection. *Respirology* 2015;20 5: 758-65.  
305


228 patients with RA underwent  
bronchoscopy

- Excluded: (n = 107)
- Active infection (n = 71)
  - Malignancy (n = 33)
  - Tracheotomy (n = 1)
  - Immunosuppressive therapy after  
solid organ transplantation (n = 1)
  - No available data (n = 1)

121 patients were enrolled

(A)

-- *P. aeruginosa*  
— Control




Number of patients at risk:

Time, years	0	2	4	6	8
<i>P. aeruginosa</i>	16	14	10	6	3
Control	84	61	38	15	10

(B)

--- *S. aureus*  
— Control




Number of patients at risk:

Time, years	0	2	4	6	8
<i>S. aureus</i>	15	9	7	3	1
Control	84	61	38	15	10

(C)

-- *H. influenzae*  
— Control



Number of patients at risk:

Time, years	0	2	4	6	8
<i>H. influenzae</i>	6	5	4	3	1
Control	84	61	38	15	10